Logo image of BJDX

BLUEJAY DIAGNOSTICS INC (BJDX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BJDX - US0956335097 - Common Stock

0.7006 USD
+0 (+0.07%)
Last: 1/21/2026, 8:00:01 PM
0.74 USD
+0.04 (+5.62%)
After Hours: 1/21/2026, 8:00:01 PM
Fundamental Rating

2

Overall BJDX gets a fundamental rating of 2 out of 10. We evaluated BJDX against 186 industry peers in the Health Care Equipment & Supplies industry. The financial health of BJDX is average, but there are quite some concerns on its profitability. BJDX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year BJDX has reported negative net income.
  • BJDX had a negative operating cash flow in the past year.
  • BJDX had negative earnings in each of the past 5 years.
  • In the past 5 years BJDX always reported negative operating cash flow.
BJDX Yearly Net Income VS EBIT VS OCF VS FCFBJDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -410.48%, BJDX is doing worse than 94.09% of the companies in the same industry.
  • BJDX's Return On Equity of -543.59% is on the low side compared to the rest of the industry. BJDX is outperformed by 82.80% of its industry peers.
Industry RankSector Rank
ROA -410.48%
ROE -543.59%
ROIC N/A
ROA(3y)-195.93%
ROA(5y)-136.14%
ROE(3y)-263.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BJDX Yearly ROA, ROE, ROICBJDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BJDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BJDX Yearly Profit, Operating, Gross MarginsBJDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

4

2. Health

2.1 Basic Checks

  • BJDX has more shares outstanding than it did 1 year ago.
  • BJDX has less shares outstanding than it did 5 years ago.
  • BJDX has a better debt/assets ratio than last year.
BJDX Yearly Shares OutstandingBJDX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
BJDX Yearly Total Debt VS Total AssetsBJDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • BJDX has an Altman-Z score of -15.01. This is a bad value and indicates that BJDX is not financially healthy and even has some risk of bankruptcy.
  • BJDX's Altman-Z score of -15.01 is on the low side compared to the rest of the industry. BJDX is outperformed by 83.33% of its industry peers.
  • BJDX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of BJDX (0.00) is better than 73.66% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.01
ROIC/WACCN/A
WACCN/A
BJDX Yearly LT Debt VS Equity VS FCFBJDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M 20M

2.3 Liquidity

  • A Current Ratio of 2.92 indicates that BJDX has no problem at all paying its short term obligations.
  • BJDX's Current ratio of 2.92 is in line compared to the rest of the industry. BJDX outperforms 56.99% of its industry peers.
  • BJDX has a Quick Ratio of 2.92. This indicates that BJDX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.92, BJDX is in the better half of the industry, outperforming 66.13% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.92
Quick Ratio 2.92
BJDX Yearly Current Assets VS Current LiabilitesBJDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 97.60% over the past year.
EPS 1Y (TTM)97.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 30.65% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y67.68%
EPS Next 2Y30.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BJDX Yearly Revenue VS EstimatesBJDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2025 2026 2M 4M 6M 8M
BJDX Yearly EPS VS EstimatesBJDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -1K -2K -3K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • BJDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BJDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BJDX Price Earnings VS Forward Price EarningsBJDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BJDX Per share dataBJDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BJDX's earnings are expected to grow with 30.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.65%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for BJDX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BLUEJAY DIAGNOSTICS INC

NASDAQ:BJDX (1/21/2026, 8:00:01 PM)

After market: 0.74 +0.04 (+5.62%)

0.7006

+0 (+0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-28
Earnings (Next)N/A
Inst Owners5.94%
Inst Owner Change0%
Ins Owners0.03%
Ins Owner Change0%
Market Cap1.27M
Revenue(TTM)N/A
Net Income(TTM)-20.07M
Analysts43.33
Price TargetN/A
Short Float %3.5%
Short Ratio0.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB 0.34
EV/EBITDA N/A
EPS(TTM)-33.6
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-3.5
FCFYN/A
OCF(TTM)-3.5
OCFYN/A
SpS0
BVpS2.04
TBVpS2.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -410.48%
ROE -543.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-195.93%
ROA(5y)-136.14%
ROE(3y)-263.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -2.81%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.92
Quick Ratio 2.92
Altman-Z -15.01
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)421.46%
Cap/Depr(5y)255.54%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.91%
EPS Next Y67.68%
EPS Next 2Y30.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y13.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.27%
OCF growth 3YN/A
OCF growth 5YN/A

BLUEJAY DIAGNOSTICS INC / BJDX FAQ

What is the ChartMill fundamental rating of BLUEJAY DIAGNOSTICS INC (BJDX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to BJDX.


Can you provide the valuation status for BLUEJAY DIAGNOSTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to BLUEJAY DIAGNOSTICS INC (BJDX). This can be considered as Overvalued.


How profitable is BLUEJAY DIAGNOSTICS INC (BJDX) stock?

BLUEJAY DIAGNOSTICS INC (BJDX) has a profitability rating of 0 / 10.


How financially healthy is BLUEJAY DIAGNOSTICS INC?

The financial health rating of BLUEJAY DIAGNOSTICS INC (BJDX) is 4 / 10.